Table of Content



1. Research Scope & Methodology
1.1. Study Objectives
1.2. Methodology
1.3. Assumptions & Limitations

2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview
2.3. Scope Of Study
2.4. Crisis Scenario Analysis
2.4.1. Impact Of Covid-19 On The China Alzheimer’S Disease Therapeutics & Diagnostics Market
2.5. Major Market Findings
2.5.1. Growing R&D Investment In The Biomarkers For Early Detection Of Dementia
2.5.2. Increasing Demand For The Personalized Medicines

3. Market Dynamics
3.1. Parent Market Analysis
3.2. Key Drivers
3.2.1. Increase In Alzheimer’S Disease Cases
3.2.2. Advancements In Diagnostic Technologies
3.2.3. Growth In The Number Of Drugs Under Development
3.2.4. Expansion Of The Elderly Population
3.3. Key Restraints
3.3.1. Limited Availability Of Surrogate Markers
3.3.2. Late-Stage Drug Failures
3.3.3. Strict Government Regulations

4. Key Analytics
4.1. Key Market Trends
4.1.1. Advancements In In-Vitro Diagnostic Techniques
4.1.2. Usage Of Computed Tomography In The Diagnostics Of Alzheimer’S Disease
4.2. Porter’S Five Forces Analysis
4.2.1. Buyers Power
4.2.2. Suppliers Power
4.2.3. Substitution
4.2.4. New Entrants
4.2.5. Industry Rivalry
4.3. Growth Prospect Mapping
4.3.1. Growth Prospect Mapping For China
4.4. Market Maturity Analysis
4.5. Market Concentration Analysis
4.6. Value Chain Analysis
4.6.1. R&D
4.6.2. Raw Material
4.6.3. Manufacturing
4.6.4. Wholesalers/Distributors/Retailers
4.6.5. End-User
4.7. Key Buying Criteria
4.7.1. Price
4.7.2. Efficiency
4.7.3. Safety
4.8. Etymology Of The China Alzheimer’S Disease Therapeutics & Diagnostics Market
4.9. Phases And Sternness Of Alzheimer’S Disease

5. Market By Product
5.1. Therapeutics
5.1.1. Cholinesterase Inhibitors
5.1.2. Nmda Receptor Antagonists
5.1.3. Other Therapeutics
5.2. Diagnostics
5.2.1. Brain Imaging
5.2.2. Csf Test For Alzheimer’S Disease
5.2.3. Other Diagnostics

6. Competitive Landscape
6.1. Key Strategic Developments
6.1.1. Mergers & Acquisitions
6.1.2. Product Launches & Developments
6.1.3. Partnerships & Agreements
6.1.4. Business Expansions & Divestitures
6.2. Company Profiles
6.2.1. Biogen Inc
6.2.1.1. Company Overview
6.2.1.2. Product List
6.2.1.3. Strengths & Challenges
6.2.2. Eli Lilly And Company
6.2.2.1. Company Overview
6.2.2.2. Product List
6.2.2.3. Strengths & Challenges
6.2.3. F Hoffmann-La Roche Ag
6.2.3.1. Company Overview
6.2.3.2. Product List
6.2.3.3. Strengths & Challenges
6.2.4. Novartis Ag
6.2.4.1. Company Overview
6.2.4.2. Products List
6.2.4.3. Strengths & Challenges
6.2.5. Johnson & Johnson
6.2.5.1. Company Overview
6.2.5.2. Product List
6.2.5.3. Strengths & Challenges
6.2.6. Merck & Co Inc
6.2.6.1. Company Overview
6.2.6.2. Product List
6.2.6.3. Strengths & Challenges
6.2.7. Pfizer Inc
6.2.7.1. Company Overview
6.2.7.2. Product List
6.2.7.3. Strengths & Challenges



List of Figures

List Of Figures
Figure 1: Key Market Trends
Figure 2: Porter’S Five Forces Analysis
Figure 3: Growth Prospect Mapping For China
Figure 4: Market Maturity Analysis
Figure 5: Market Concentration Analysis
Figure 6: Value Chain Analysis
Figure 7: Key Buying Criteria
Figure 8: China Alzheimer’S Disease Therapeutics & Diagnostics Market, Growth Potential, By Product, In 2023
Figure 9: China Alzheimer’S Disease Therapeutics & Diagnostics Market, By Therapeutics, 2024-2032 (In $ Million)
Figure 10: China Alzheimer’S Disease Therapeutics & Diagnostics Market, Growth Potential, By Therapeutics, In 2023
Figure 11: China Alzheimer’S Disease Therapeutics & Diagnostics Market, By Cholinesterase Inhibitors, 2024-2032 (In $ Million)
Figure 12: China Alzheimer’S Disease Therapeutics & Diagnostics Market, By Nmda Receptor Antagonists, 2024-2032 (In $ Million)
Figure 13: China Alzheimer’S Disease Therapeutics & Diagnostics Market, By Other Therapeutics, 2024-2032 (In $ Million)
Figure 14: China Alzheimer’S Disease Therapeutics & Diagnostics Market, By Diagnostics, 2024-2032 (In $ Million)
Figure 15: China Alzheimer’S Disease Therapeutics & Diagnostics Market, Growth Potential, By Diagnostics, In 2023
Figure 16: China Alzheimer’S Disease Therapeutics & Diagnostics Market, By Brain Imaging, 2024-2032 (In $ Million)
Figure 17: China Alzheimer’S Disease Therapeutics & Diagnostics Market, By Csf Test For Alzheimer’S Disease, 2024-2032 (In $ Million)
Figure 18: China Alzheimer’S Disease Therapeutics & Diagnostics Market, By Other Diagnostics, 2024-2032 (In $ Million)

List of Tables

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS
TABLE 2: CHINA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET REGULATORY FRAMEWORK
TABLE 3: CHINA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 4: CHINA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY PRODUCT, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 5: KEY PLAYERS OPERATING IN CHINA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
TABLE 6: LIST OF MERGERS & ACQUISITIONS
TABLE 7: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 8: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 9: LIST OF BUSINESS EXPANSIONS & DIVESTITURES